Summary
In a double blind study 8 patients with uncomplicated essential hypertension received in random order single oral doses of placebo and 10, 30 and 80 mg Ro 23-6152, a novel calcium entry blocker, on 4 different days. Patients were assessed 15 min before dosing and at several time intervals over the following 6 h.
Ro 23-6152 30 and 80 mg induced a significant decrease (mean maximum 7 mmHg·l−1·min−1) in total peripheral resistance, while cardiac output, stroke volume and heart rate were slightly increased (mean maximum 0.5 l·min−1, 10 ml, 5 beats·min−1, respectively) but not significantly so. Systolic blood pressure decreased significantly (5 to 10 mm Hg) from 0.5 to 6 h after the 80 mg dose. After the 10 and 30 mg doses the decreases in systolic pressure were not significant. Diastolic blood pressure and mean arterial blood pressure were non-significantly decreased (mean maximum 7 mm Hg) after all doses. The PQ interval was also non-significantly increased by no more than 20 ms.
It appears that the main hemodynamic effect of Ro 23-6152 in hypertensive patients is a decrease in peripheral resistance. The antihypertensive effect, at least in this short term study, was only modest, probably because the fall in peripheral resistance was partly compensated by an increase in cardiac output.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rosenberger LB, Ticku MK, Triggle DJ (1979) The effect of Ca + + antagonists on mechanical responses and Ca + + movements in guinea pig ileal, longitudinal smooth muscle. Can J Physiol Pharmacol 57: 333–347
Chaffman M, Brogden RN (1985) Diltiazem, a review of its pharmacological properties and therapeutic efficacy. Drugs ADIS Press Ltd, Aukland 29: 387–454
Bianchetti MG, Beretta-Picolli C, Weidman P (1983) Calcium and blood pressure regulation in normal and hypertensive subjects. Hypertension 5 [Suppl II]: 56–65
Evans JM (1987) Measurement of blood flow volume rate by Doppler ultrasound. PhD thesis, University of Bristol, England
Evans JM, Skidmore R, Baker JD, Wells PNT (1989) A new approach to the non-invasive measurement of cardiac output using annular array Doppler techniques. Ultrasound Med Biol 15: 169–187
Taylor SH, Silke B (1988) Is the measurement of cardiac output useful in clinical practice? Br J Anaesth 60 [Suppl]: 90S-98S
Huntsman LL, Stewart DK, Barnes SR, Franklin BS, Colocousis JS, Hessel EA (1983) Noninvasive doppler determination of cardiac output in man, clinical validation. Circulation 67: 593–602
Lederballe Pedersen O (1981) Calcium Blockade as a Therapeutic Principle in Arterial Hypertension. Thesis, Aarhus, Denmark
Aoki K, Yoshida T, Kato S, Tazumi K, Sato I, Takikawa K, Hotta K (1976) Hypotensive action and increased plasma renin activity by Ca + + antagonist (nifedipine) in hypertensive patients. Jpn Heart J 17: 479–484
Guazzi M, Olivari MT, Polese A, Fiorentini C, Magrini F, Moruzzi P (1977) Nifedipine, a new antihypertensive with rapid action. Clin Pharmacol Ther 22: 528–532
Olivari MT, Bartorelli C, Polese A, Fiorentini C, Morruzi P, Guazzi MP (1979) Treatment of hypertension with nifedipine, a calcium antagonistic agent. Circulation 59: 1056–1062
Vincenzi M, Allegri P, Gabaldo S, Maiolino P, Ometto R (1976) Haemodynamic effects caused by i.v. administration of verapamil in healthy subjects. Arzneimittelforsch Drug Res 26: 1221–1223
Schmieder RE, Messerli FH, Guillermo E, Garavaglia GE, Nunez BD (1987) Cardiovascular effects of verapamil in patients with essential hypertension. Circulation 75: 1030–1036
Gould BA, Mann S, Kieso H, Bala Subramanian V, Raftery EB (1982) The 24-hour ambulatory blood pressure profile with verapamil. Circulation 65: 22–27
Lund-Johansen P (1984) Haemodynamic effects of verapamil in essential hypertension at rest and during exercise. Acta Med Scand [Suppl] 681: 109–115
Klein W, Brandt D, Vrecko K, Härringer M (1983) Role of calcium antagonists in the treatment of essential hypertension. Circ Res 52 [Suppl 11]: 174–181
Schulte KL, Meyer Sabellek WA, Distler A, Gotzen R (1984) Longterm treatment with diltiazem and nifedipine in essential hypertension. J Hypertension 2: 93
Yamakado T, Oonishi N, Kondo S, Noriza A, Nakano T, Takazama H (1983) Effects of diltiazem on cardiovascular responses during exercise in systemic hypertension and comparison with propanolol. Am J Cardiol 52: 1023–1027
Lederballe Pedersen O, Mikkelsen E, Anderson KE (1978) Effects of extracellulair calcium on potassium and noradrenaline induced contractions in the aorta of spontaneous hypertensive rats-Increased sensitivity to nifedipine. Acta Pharmacol Toxicol 43: 137–144
Moichizuki A, Aoki K, Kondo S, Aoki K, Mizuno T, Hotta K (1979) Specificity of tension development and calcium flux of the arterial smooth muscle in SHR. Jpn Heart J 20 [Suppl 1]: 225–227
Lederballe Pedersen O, Christensen NJ, Ramsch KD (1980) Comparison of acute effects of nifedipine in normotensive and hypertensive man. J Cardiovasc Pharmacol 2: 357–366
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Folkers, H.B.M., van Zwienen, J.C.W., Boer, P. et al. Hemodynamic effects of Ro 23-6152 in patients with essential hypertension. Eur J Clin Pharmacol 41, 307–311 (1991). https://doi.org/10.1007/BF00314957
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00314957